Clinical trial NCT03156595: Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies
Official title: Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chemotherapy-induced Neuropathy
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2017-05-17
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chimiotherapy produces neuropathies injuries to 30% to 70% cases. A third of those patients keeps suffering from this side effects disabilities and their quality of life is seriously affected.

Hypnosis, as a non-invasive tool without physical side effects, might be used to relieve them.

the purpose of this trial based on our own experience, is to demonstrate the value of using hypnosis and self-hypnosis in chimiotherapy- induced chronic neuropathies.

The aim will be to sustainably improve the quality of life by expanding self-management of pain and motor function side effect.


Eligibility criteria: Inclusion Criteria:

* Minimum age :18 years
* Chemiotherapy- induced chronic neuropathies for at least 2 months with a DN4 score \>4
* Failure of classic treatment used to relief neuropathic
* Having stopped chemotherapy treatment and being in complete or partial response or in tumoral stability
* Without any planed chemiotherapy during the study
* Having signed a written informed consent.
* French efficient understanding
* With health insurance coverage
* availability during all the study
* With efficient contraception for women of childbearing age

Exclusion Criteria:

* No participation to another study at the same time
* Suffering from neuropathy before having chemotherapy
* Other disease that may cause neuropathy
* deafness
* Any medicine that could cause neuropathy
* Neurological or psychiatrical disease past or present
* Mental retardation
* Allergy to EMG's electrodes
* Unable to consent, under tutelage or curatorship or judiciary safeguard
* Pregnant or nursing woman

Primary outcomes:
measure: Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the sensitive dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.
timeFrame: Day 84
Secondary outcomes:
measure: Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the motor dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.
timeFrame: Day 84
measure: Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the loss of autonomy of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.
timeFrame: Day 84
measure: Measure benefits of hypnosis on the neuropathic pain intensity
timeFrame: Day 28, day 56 and Day 84.
measure: Measure benefits of hypnosis on a psychotropic treatments
timeFrame: Day 0, Day 28, day 56 and Day 84.
measure: Measure benefits of hypnosis on analgesic treatments
timeFrame: Day 0, Day 28, day 56 and Day 84.
measure: Measure benefits of hypnosis on tendon reflexes, deep and superficial sensitivity, muscular strength
timeFrame: Day 84
measure: Measure benefits of hypnosis on electrophysiological abnormalities related to neuropathy
timeFrame: Day 84
measure: Measure benefits of hypnosis on self- hypnosis in the experimental group
timeFrame: Day 28, Day 56 and D84
measure: Evaluate the safety in the two arms, due to hypnosis adverse effects, to pain treatment or another reason
timeFrame: Day 0, Day 28, Day 56, Day 84 and in case of serious adverse event
Other outcomes:
Locations:
city: Strabsourg
country: France
facility: University Strasbourg Hospital
Study officials:
affiliation: Strasbourg's University Hospitals
name: Caroline MAURER, Nurse
role: STUDY_CHAIR
affiliation: Strasbourg's University Hospitals
name: Raoul HERBRECHT, MD
role: PRINCIPAL_INVESTIGATOR
References: